New literature shows the positive impact pharmacists can have to increase adherence, manage adverse effects, and provide supportive care to patients taking oral chemotherapy. Tune in this month to learn how you can play a role to improve the quality of life for your patients. 

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Outline common toxicities of oral oncolytics
2. Evaluate different toxicity management strategies for patients taking oral oncolytics
3. Analyze the current evidence on patient-reported outcome measurement for oral oncolytic symptoms and adherence
4. Assess strengths and limitations of a recent observational study on oral oncolytics
5. Identify strategies for pharmacists to impact oncology patient adherence and quality of life

Erin Kelley, PharmD, BCOP
Oncology Clinical Pharmacist
M Health Fairview

Erin Kelley does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Nachar VR, Farris K, Beekman K, et al. Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM). JCO Clin Cancer Inform. 2019 May;3:1-6. doi: 10.1200/CCI.18.00128. PMID: 31100014.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: December 8, 2021
Planned Expiration Date: December 8, 2024